Daiichi Sankyo initiates Phase 3 trial for Destiny-Breast11 neoadjuvant therapy

Destiny-Breast11 will evaluate Enhertu as a monotherapy or Enhertu followed by paclitaxel, trastuzumab and pertuzumab

U.S. FDA grants breakthrough designation to Datar’s blood test to detect breast cancer

It is the first blood test able to detect early-stage Breast Cancer with high accuracy in women above the age of 40 years

Novartis’ Kisqali data indicates longest median survival in advanced breast cancer

With the MONALEESA-2 final analysis, only Kisqali has reported statistically significant overall survival (OS) benefit with an aromatase inhibitor for postmenopausal women with HR+/HER2- advanced breast cancer in the first-line (1L) setting

Merck reports breakthrough Phase 3 win for sac-TMT in endometrial cancer

Women’s hospital opens in Delhi with $5 million backing

30,000 sq. ft. multispeciality facility aims to deliver integrated care for women across every life stage

Merck to showcase 100+ oncology studies at 2026 ASCO meeting

Highlighting KEYTRUDA & expanding cancer pipeline

Gufic Biosciences deepens global oncology push with fresh investment in Australia’s Selvax

Selvax, founded in 1987, is focused on developing novel immunotherapy solutions with applications in both human and veterinary oncology

Pfizer unleashes wave of breakthrough cancer data at ASCO 2026

Pharma giant targets new standards of care

Samsung Bioepis unveils promising preclinical data for novel ADC SBE303 at AACR 2026

SBE303 targets Nectin-4, an adhesion protein overexpressed in multiple tumor types, including urothelial, lung, and breast cancers

HCG Cancer Hospital, Borivali hosts ROBOCAN 1.0 to advance robotic cancer surgery adoption

Experts highlighted how robotic-assisted procedures are improving surgical precision, reducing complications, and enabling faster recovery